AR063618A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR063618A1
AR063618A1 ARP070104976A ARP070104976A AR063618A1 AR 063618 A1 AR063618 A1 AR 063618A1 AR P070104976 A ARP070104976 A AR P070104976A AR P070104976 A ARP070104976 A AR P070104976A AR 063618 A1 AR063618 A1 AR 063618A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
isoindoline
pentamethyl
absorbability
benzofuran
Prior art date
Application number
ARP070104976A
Other languages
English (en)
Inventor
Satoshi Linuma
Kazhisa Kamikaua
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR063618A1 publication Critical patent/AR063618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una composición farmacéutica que comprende (1) (R)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metil-fenil)-2,3-dihidro-1-benzofuran-5-il]isoindolina, ( 2) un componente lipofílico y (3) un agente tensioactivo, que puede proveer en forma estable y suficiente mejoramiento de la absorbabilidad del fármaco sin ser afectado por la cantidad y calidad de una comida.
ARP070104976A 2006-11-09 2007-11-08 Composicion farmaceutica AR063618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006303800 2006-11-09

Publications (1)

Publication Number Publication Date
AR063618A1 true AR063618A1 (es) 2009-02-04

Family

ID=38942774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104976A AR063618A1 (es) 2006-11-09 2007-11-08 Composicion farmaceutica

Country Status (11)

Country Link
US (1) US20100273852A1 (es)
EP (1) EP2079455B1 (es)
JP (1) JP2010509188A (es)
AR (1) AR063618A1 (es)
AT (1) ATE456365T1 (es)
CA (1) CA2668864A1 (es)
CL (1) CL2007003217A1 (es)
DE (1) DE602007004642D1 (es)
PE (1) PE20081491A1 (es)
TW (1) TW200833374A (es)
WO (1) WO2008056822A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
KR100660788B1 (ko) * 1998-12-04 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체, 그 제조법 및 용도
US20030149061A1 (en) * 2000-04-04 2003-08-07 Yoshitaka Nishihara Oily compositions containing highly fat-soluble drugs
CA2432410A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Process for preparing optically active 2,3-dihydro- benzofuran compounds
AU2002366313A1 (en) * 2001-12-19 2003-06-30 Takeda Chemical Industries, Ltd. Solid compositions containng compounds unstable to oxygen and method for stabilization thereof
PL371366A1 (en) * 2002-03-01 2005-06-13 Takeda Pharmaceutical Company Limited Antidepressant

Also Published As

Publication number Publication date
EP2079455B1 (en) 2010-01-27
JP2010509188A (ja) 2010-03-25
DE602007004642D1 (de) 2010-03-18
TW200833374A (en) 2008-08-16
EP2079455A1 (en) 2009-07-22
WO2008056822A1 (en) 2008-05-15
CA2668864A1 (en) 2008-05-15
ATE456365T1 (de) 2010-02-15
CL2007003217A1 (es) 2008-07-04
US20100273852A1 (en) 2010-10-28
PE20081491A1 (es) 2008-11-12

Similar Documents

Publication Publication Date Title
EA201070568A1 (ru) Фармацевтические составы
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
UY31647A1 (es) Forma de dosificación farmacéutica para la administración oral de inhibidor de tirosina quinasa
CY1113128T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
ECSP088239A (es) Composición de liberación de fármaco sostenida
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
MA30765B1 (fr) Derives innovants du thiophene
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
ATE555777T1 (de) Pharmazeutische zusammensetzung
CL2007002421A1 (es) Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
EA201170512A1 (ru) Композиция для перорального введения
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
CR9632A (es) Tableta que contiene un ingrediente dificilmente soluble
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
EA201100752A1 (ru) Фармацевтические пероральные композиции с пролонгированным высвобождением, включающие производные 2-оксо-1-пирролидина
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).

Legal Events

Date Code Title Description
FB Suspension of granting procedure